Overview

An Extension Study of PEAK Trial

Status:
Terminated

Trial end date:
2019-02-28

Target enrollment:

Participant gender:

Summary

Double blind, three arm, comparative intervention trial for 24 weeks(PEAK study) with open label extension trial for 28 weeks followed by 2 year observational study.

Phase:

Phase 4

Details

Lead Sponsor:

Kun-Ho Yoon

Collaborator:

Takeda

Treatments:

Alogliptin
Metformin
Pioglitazone